Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Leuk Lymphoma
    September 2025
  1. ELGHAWY O, Swami N, Hing ZA, Barta SK, et al
    Advances in T-cell lymphomas and risk factors for CNS involvement.
    Leuk Lymphoma. 2025;66:1583-1602.
    >> Share

  2. SHAH B, Challagulla S, Xu S, Williams R, et al
    Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2541911.
    >> Share

    August 2025
  3. MEEUWES FO, Serroukh YIM, van der Poel MWM, Plattel WJ, et al
    Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives.
    Leuk Lymphoma. 2025 Aug 28:1-16. doi: 10.1080/10428194.2025.2545927.
    >> Share

  4. CHUMNUMSIRIWATH P, Vittayawacharin P, Pinter-Brown L, Brem EA, et al
    Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.
    Leuk Lymphoma. 2025 Aug 21:1-5. doi: 10.1080/10428194.2025.2547985.
    >> Share

  5. ISKIERKA-JAZDZEWSKA E, Kim WS, Cho SG, Kim TM, et al
    Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.
    Leuk Lymphoma. 2025 Aug 20:1-12. doi: 10.1080/10428194.2025.2535694.
    >> Share

  6. MATARASSO GREENFELD S, Dmitrienko S, Shrier I, Deschenes JL, et al
    Understanding the clinical approach to "pathologically ambiguous follicular lymphoma" through a Real-World cohort.
    Leuk Lymphoma. 2025 Aug 18:1-4. doi: 10.1080/10428194.2025.2542943.
    >> Share

  7. TOLU SS, Gribbin C, Chen Z, Seshadri MR, et al
    Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
    Leuk Lymphoma. 2025 Aug 14:1-11. doi: 10.1080/10428194.2025.2540437.
    >> Share

  8. JEFFREY A, Favaloro J, Wolyncewicz G, Horgan L, et al
    Spontaneous remission of Epstein-Barr virus positive diffuse large B-cell lymphoma after relapse post axicabtagene ciloleucel chimeric antigen receptor T-cell therapy.
    Leuk Lymphoma. 2025 Aug 12:1-5. doi: 10.1080/10428194.2025.2545928.
    >> Share

  9. GORDON ER, Tolu S, Lapolla BA, Trager MH, et al
    Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2025 Aug 11:1-8. doi: 10.1080/10428194.2025.2542941.
    >> Share

  10. ZHOU X, Ling Y, Ma J, Lin Z, et al
    Clinical characteristics and prognosis of primary central nervous system lymphoma in China: a single-center retrospective analysis of 325 patients.
    Leuk Lymphoma. 2025 Aug 8:1-12. doi: 10.1080/10428194.2025.2541016.
    >> Share

  11. SHARIFF N, Chun FJ, Parsons SK, Hodgson DC, et al
    The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review.
    Leuk Lymphoma. 2025 Aug 8:1-13. doi: 10.1080/10428194.2025.2531154.
    >> Share

  12. SUPERDOCK MA, Rimsza LM, Wallace DS, Strawderman M, et al
    Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study.
    Leuk Lymphoma. 2025 Aug 6:1-4. doi: 10.1080/10428194.2025.2539231.
    >> Share

  13. XIAO A, Chen L, Pak S, Lee B, et al
    Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma.
    Leuk Lymphoma. 2025 Aug 5:1-9. doi: 10.1080/10428194.2025.2540442.
    >> Share

  14. FUJINO T, Okamoto H, Nishiyama D, Hayata H, et al
    Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.
    Leuk Lymphoma. 2025;66:1425-1436.
    >> Share

    July 2025
  15. ABRAMSON JS, Kamdar M, Liu FF, Crotta A, et al
    Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma.
    Leuk Lymphoma. 2025 Jul 24:1-14. doi: 10.1080/10428194.2025.2532674.
    >> Share

  16. KITAMURA A, Shiroshita K, Fujita S, Kudo H, et al
    Unexpected progression of lymphoplasmacytic lymphoma with TP53 deletion after treatment for concurrent multiple myeloma with IGH::CCND1.
    Leuk Lymphoma. 2025 Jul 24:1-5. doi: 10.1080/10428194.2025.2536126.
    >> Share

  17. HU W, Landgren O, Bassig BA, Purdue MP, et al
    Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study.
    Leuk Lymphoma. 2025 Jul 16:1-8. doi: 10.1080/10428194.2025.2524505.
    >> Share

  18. WU Y, Ke Q, Liu B, Luo W, et al
    KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications.
    Leuk Lymphoma. 2025 Jul 15:1-5. doi: 10.1080/10428194.2025.2532680.
    >> Share

  19. ISMAYILOV R, Ozdede M, Uner A, Barista I, et al
    Machine learning-based risk prediction model for central nervous system involvement in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2025 Jul 12:1-10. doi: 10.1080/10428194.2025.2526793.
    >> Share

  20. IZUTSU K, Akahane D, Toubai T, Saito T, et al
    Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.
    Leuk Lymphoma. 2025 Jul 9:1-9. doi: 10.1080/10428194.2025.2525983.
    >> Share

  21. ANDREADIS C, Bobek O, Hsi ED, Fenske TS, et al
    Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup doub
    Leuk Lymphoma. 2025 Jul 9:1-10. doi: 10.1080/10428194.2025.2525982.
    >> Share

  22. MEEUWES FO, Brink M, van der Poel MWM, Serroukh YIM, et al
    Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands.
    Leuk Lymphoma. 2025 Jul 9:1-7. doi: 10.1080/10428194.2025.2530167.
    >> Share

  23. UYANIK MS, Jabbour E, Short N, Sasaki K, et al
    Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients.
    Leuk Lymphoma. 2025 Jul 6:1-3. doi: 10.1080/10428194.2025.2521649.
    >> Share

  24. LUTTWAK E, Robin ET, Drill E, Boardman A, et al
    Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.
    Leuk Lymphoma. 2025;66:1276-1283.
    >> Share

  25. MAURER K, Jacobson CA
    T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies.
    Leuk Lymphoma. 2025;66:1189-1197.
    >> Share

    June 2025
  26. DERENZINI E, Gibb A, Kwiatek M, Strati P, et al
    Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.
    Leuk Lymphoma. 2025 Jun 30:1-13. doi: 10.1080/10428194.2025.2520440.
    >> Share

  27. SLATER VE, Carnahan RM, Strouse CS, O'Rorke MA, et al
    Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373.
    >> Share

  28. PREM SUDHA S, Shehata A, Al-Ali F, Abdelfattah N, et al
    Use of doxorubicin is not associated with hemolytic complications in severely G6PD deficient patients with lymphoma.
    Leuk Lymphoma. 2025 Jun 24:1-7. doi: 10.1080/10428194.2025.2521654.
    >> Share

  29. KURUVILLA J, Modi D, Santoro A, Paszkiewicz-Kozik E, et al
    Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.
    Leuk Lymphoma. 2025 Jun 23:1-10. doi: 10.1080/10428194.2025.2502805.
    >> Share

  30. DANDAMUDI DB, Konieczna IM, Calabrese KM, Wielgos-Bonvallet M, et al
    Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2025 Jun 18:1-12. doi: 10.1080/10428194.2025.2504719.
    >> Share

  31. LIN MH, Weiss J, Phillips TJ, Sano D, et al
    Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.
    Leuk Lymphoma. 2025 Jun 9:1-13. doi: 10.1080/10428194.2025.2506498.
    >> Share

  32. LAKHOTIA R, Melani C, Dunleavy K, Pittaluga S, et al
    Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.
    Leuk Lymphoma. 2025;66:1088-1099.
    >> Share

    May 2025
  33. RASMUSSEN LA, Vedsted P, Jensen H, Frederiksen H, et al
    Lymphoma: factors associated with unplanned diagnostic pathways and survival -a nationwide Danish register-based cohort study.
    Leuk Lymphoma. 2025 May 27:1-12. doi: 10.1080/10428194.2025.2508299.
    >> Share

  34. MESTNIK S, Marley AR, Lu Z, Turcotte LM, et al
    Childhood body mass index at diagnosis and its association with non-Hodgkin lymphoma in the United States: a children's oncology group data analysis project.
    Leuk Lymphoma. 2025 May 26:1-6. doi: 10.1080/10428194.2025.2506502.
    >> Share

  35. BUCALOIU A, Jamshidi P, Dixit K, Sukhanova M, et al
    Diagnostic utility of plasma circulating tumor DNA (ctDNA) in primary large B-cell lymphoma of the central nervous system (PCNS-LBCL): A paradigm shift?
    Leuk Lymphoma. 2025 May 23:1-4. doi: 10.1080/10428194.2025.2508298.
    >> Share

  36. HILL BT, Torka P, Hernandez-Ilizaliturri F, Dean R, et al
    Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.
    Leuk Lymphoma. 2025 May 21:1-10. doi: 10.1080/10428194.2025.2504156.
    >> Share

  37. ROBAK E, Braun M, Robak T
    A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type.
    Leuk Lymphoma. 2025 May 20:1-12. doi: 10.1080/10428194.2025.2506503.
    >> Share

  38. BALAN K, Aslan M, Ayhan EA, Akin S, et al
    Double hit lymphoma masqueraded as clusters of crater-like nonhealing infectious skin lesions.
    Leuk Lymphoma. 2025 May 9:1-3. doi: 10.1080/10428194.2025.2503464.
    >> Share

  39. CRUZ CA, Rodriguez ER, Thawani M, Mazer M, et al
    Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma.
    Leuk Lymphoma. 2025 May 8:1-7. doi: 10.1080/10428194.2025.2499607.
    >> Share

  40. OTHMAN T, Lo MM, Andreadis CB, Damon LE, et al
    Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2025 May 7:1-4. doi: 10.1080/10428194.2025.2496333.
    >> Share

  41. HAYDON MD, Hwang AE, Wade NB, Wang J, et al
    Adverse late outcomes in long-term survivors of young adult Hodgkin lymphoma (YAHL) compared to their unaffected co-twins.
    Leuk Lymphoma. 2025 May 1:1-10. doi: 10.1080/10428194.2025.2476664.
    >> Share

    April 2025
  42. PUCKRIN R
    The paradox of the spleen: is it a nodal or extranodal site of lymphoma?
    Leuk Lymphoma. 2025 Apr 22:1-3. doi: 10.1080/10428194.2025.2495112.
    >> Share

  43. MAHMOUDJAFARI Z, Di Maio D, Li J, Rosettie KL, et al
    Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis(double dagger).
    Leuk Lymphoma. 2025 Apr 9:1-8. doi: 10.1080/10428194.2025.2486437.
    >> Share

  44. ANDERSON E, Choi Y, Buchsbaum RJ, Klein A, et al
    Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.
    Leuk Lymphoma. 2025 Apr 8:1-10. doi: 10.1080/10428194.2025.2484367.
    >> Share

  45. WANG W, Chen M, Li J, Liu J, et al
    Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma.
    Leuk Lymphoma. 2025 Apr 2:1-6. doi: 10.1080/10428194.2025.2484365.
    >> Share

    March 2025
  46. GARG M, Satija A, Song Y, Sarpong EM, et al
    Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.
    Leuk Lymphoma. 2025 Mar 31:1-10. doi: 10.1080/10428194.2025.2482136.
    >> Share

  47. VODICKA P, Masar M, Benesova K, Koren J, et al
    The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.
    Leuk Lymphoma. 2025 Mar 31:1-7. doi: 10.1080/10428194.2025.2475327.
    >> Share

  48. OWEN C, Mojtabavi A, Buckland T, Dean M, et al
    Analysis of a cancer-care based diagnosis program for lymphoma.
    Leuk Lymphoma. 2025 Mar 26:1-6. doi: 10.1080/10428194.2025.2482890.
    >> Share

  49. ONISHI A, Miyagawa-Hayashino A, Okamoto H, Fujino T, et al
    Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.
    Leuk Lymphoma. 2025 Mar 25:1-12. doi: 10.1080/10428194.2025.2482891.
    >> Share

  50. ROBAK T, Pluta A, Robak P, Janus A, et al
    Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.
    Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337.
    >> Share

  51. JAIN N, Eyre TA, Winfree KB, Bhandari NR, et al
    Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Mar 23:1-13. doi: 10.1080/10428194.2025.2482132.
    >> Share

  52. DAUNOV M, Deng C
    Twice the trouble, half the fun: twin study suggests future direction for young adults with Hodgkin lymphoma.
    Leuk Lymphoma. 2025 Mar 14:1-3. doi: 10.1080/10428194.2025.2476650.
    >> Share

  53. STEWART C, Owen C, Street L, Hay K, et al
    Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate.
    Leuk Lymphoma. 2025 Mar 11:1-4. doi: 10.1080/10428194.2025.2477725.
    >> Share

  54. MAJOR A, Palese M, Jones A, Goes M, et al
    Patient and care partner perspectives on treatment decision-making in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): a Global nLPHL One Working Group (GLOW) study.
    Leuk Lymphoma. 2025 Mar 10:1-5. doi: 10.1080/10428194.2025.2474080.
    >> Share

  55. TUCCI A, Re A, Pagani C, Marcheselli L, et al
    A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.
    Leuk Lymphoma. 2025 Mar 8:1-9. doi: 10.1080/10428194.2025.2471499.
    >> Share

  56. LEE J, Song SY, Shin YS, Kim SW, et al
    Deintensification of radiation dose to 20 Gy for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.
    Leuk Lymphoma. 2025 Mar 6:1-8. doi: 10.1080/10428194.2025.2470777.
    >> Share

  57. KIM MJ, Cho J, Kim WS, Kim SJ, et al
    Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma.
    Leuk Lymphoma. 2025 Mar 3:1-12. doi: 10.1080/10428194.2025.2471500.
    >> Share

    February 2025
  58. GURUMURTHI A, Henshaw L, Falchi L, Moskowitz A, et al
    Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naive Hodgkin lymphoma.
    Leuk Lymphoma. 2025 Feb 24:1-4. doi: 10.1080/10428194.2025.2470776.
    >> Share

  59. ABEYAKOON C, Ting E, Khan S, Maganti M, et al
    Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada.
    Leuk Lymphoma. 2025 Feb 21:1-5. doi: 10.1080/10428194.2025.2467801.
    >> Share

  60. SHESTAKOVA A, Haghighi N, Zhang Y, Tarabay J, et al
    Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.
    Leuk Lymphoma. 2025 Feb 18:1-6. doi: 10.1080/10428194.2025.2452341.
    >> Share

  61. GAMBELLA M, Carlomagno S, Raiola AM, Sivori S, et al
    (CAR-)T cell dynamics following chimeric antigen receptor T cells for large B cell lymphoma: a translational tale.
    Leuk Lymphoma. 2025 Feb 13:1-9. doi: 10.1080/10428194.2025.2456096.
    >> Share

  62. FREY C, Etminan M
    Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma.
    Leuk Lymphoma. 2025 Feb 12:1-3. doi: 10.1080/10428194.2025.2461663.
    >> Share

  63. HORWITZ SM, Feldman TA, Ye JC, Khodadoust MS, et al
    Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
    Leuk Lymphoma. 2025 Feb 8:1-11. doi: 10.1080/10428194.2025.2455489.
    >> Share

  64. XIONG S, Zhang S, Yue N, Cao J, et al
    CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges.
    Leuk Lymphoma. 2025 Feb 3:1-13. doi: 10.1080/10428194.2025.2458214.
    >> Share

    January 2025
  65. FEDELE PL, Opat S
    Indolent lymphoma: addressing the needs of survivors.
    Leuk Lymphoma. 2025 Jan 28:1-15. doi: 10.1080/10428194.2025.2456970.
    >> Share

  66. GAULIN C, Jain P, Nair R, Iyer SP, et al
    Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.
    Leuk Lymphoma. 2025 Jan 21:1-5. doi: 10.1080/10428194.2025.2454540.
    >> Share

  67. CENCINI E, Palazzo M, Dardanis D, Lucco Navei G, et al
    Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).
    Leuk Lymphoma. 2025 Jan 21:1-10. doi: 10.1080/10428194.2025.2456094.
    >> Share

  68. WANG Y, Han J, Yin S, Yang S, et al
    Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system.
    Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2451066.
    >> Share

  69. BENNETT R, Juneja M, Anderson MA, Minson A, et al
    Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses.
    Leuk Lymphoma. 2025 Jan 14:1-4. doi: 10.1080/10428194.2025.2451725.
    >> Share

  70. RUSCONI C, Barone A, Visentin A, Bianchi B, et al
    Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD.
    Leuk Lymphoma. 2025 Jan 11:1-9. doi: 10.1080/10428194.2024.2446609.
    >> Share

  71. HARRIS W, Cao Y, Morschhauser F, Salles G, et al
    gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles.
    Leuk Lymphoma. 2025 Jan 10:1-8. doi: 10.1080/10428194.2024.2446613.
    >> Share

  72. VARTANOV AR, Hasler JS, Handorf EA, Frosch ZAK, et al
    Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2025 Jan 8:1-4. doi: 10.1080/10428194.2025.2450091.
    >> Share

  73. GAO Y, Zhang L, Gao S, Yang Y, et al
    Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial.
    Leuk Lymphoma. 2025 Jan 7:1-11. doi: 10.1080/10428194.2024.2439525.
    >> Share

  74. GRUNBLATT E, Meng Z, Baldridge AS, Patel NP, et al
    Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.
    Leuk Lymphoma. 2025 Jan 7:1-11. doi: 10.1080/10428194.2024.2448713.
    >> Share

  75. LUTTWAK E, Kumar A, Salles G
    Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.
    Leuk Lymphoma. 2025 Jan 5:1-12. doi: 10.1080/10428194.2024.2447371.
    >> Share

  76. JIN J, Meng DD, Wen Y, Zhang QL, et al
    PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.
    Leuk Lymphoma. 2025 Jan 5:1-10. doi: 10.1080/10428194.2024.2447888.
    >> Share

  77. ALMEIDA PM, Relander T, Linden O
    Salvage therapy for Burkitt lymphoma with glofitamab: a case report.
    Leuk Lymphoma. 2025 Jan 3:1-4. doi: 10.1080/10428194.2024.2447882.
    >> Share

  78. EICHENAUER DA, Borchmann P
    Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.
    Leuk Lymphoma. 2025 Jan 2:1-8. doi: 10.1080/10428194.2024.2447886.
    >> Share

    December 2024
  79. NG LCK, Ong SY, Huang X, Ghosh A, et al
    Outcome of extra-nodal follicular lymphoma affected by choice of induction chemoimmunotherapy and maintenance rituximab - real-world retrospective study.
    Leuk Lymphoma. 2024 Dec 28:1-7. doi: 10.1080/10428194.2024.2446615.
    >> Share

  80. OTHMAN T, Marquez-Arreguin G, Esteghamat N, Tuscano J, et al
    A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma.
    Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2443552.
    >> Share

  81. TINAJERO J, Markary T, Ngo D, Kambhampati Thiruvengadam S, et al
    Glofitamab in patients with HIV-associated B-cell lymphoma.
    Leuk Lymphoma. 2024 Dec 23:1-4. doi: 10.1080/10428194.2024.2444470.
    >> Share

  82. GRIGG S, Lade S, Ryland G, Grimmond S, et al
    Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma.
    Leuk Lymphoma. 2024 Dec 22:1-4. doi: 10.1080/10428194.2024.2443561.
    >> Share

  83. KIM K, Chihara D
    The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma.
    Leuk Lymphoma. 2024 Dec 17:1-11. doi: 10.1080/10428194.2024.2436606.
    >> Share

  84. MUNOZ J, Tsang M, Wang Y, Phillips T, et al
    Challenges of treating mantle cell lymphoma in older adults.
    Leuk Lymphoma. 2024 Dec 11:1-18. doi: 10.1080/10428194.2024.2431563.
    >> Share

  85. SHUMILOV E, Levien L, Mazzeo P, Jung W, et al
    Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning.
    Leuk Lymphoma. 2024 Dec 11:1-12. doi: 10.1080/10428194.2024.2438805.
    >> Share

  86. ANDERSEN MD, Wolter K, Enemark MH, Lauridsen KL, et al
    Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity.
    Leuk Lymphoma. 2024 Dec 3:1-12. doi: 10.1080/10428194.2024.2434170.
    >> Share

  87. TEOH XY, Mashor Mansor M, Mohd Affandi A, Awang A, et al
    Spontaneous regression of cutaneous T cell lymphoma in an HIV-positive patient.
    Leuk Lymphoma. 2024 Dec 2:1-2. doi: 10.1080/10428194.2024.2433616.
    >> Share

  88. GORDON ER, Trager MH, Kwinta BD, Stonesifer CJ, et al
    Maintenance therapy for CTCL: importance for prevention of disease progression.
    Leuk Lymphoma. 2024;65:1883-1890.
    >> Share

  89. KURUCU N, Kutluk T, Saglam A, Cagdas D, et al
    Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity.
    Leuk Lymphoma. 2024;65:1875-1882.
    >> Share

  90. MINA A
    Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
    Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575.
    >> Share

  91. JAMAL E, Poynton E, Elbogdady M, Shamaa S, et al
    Prospects for liquid biopsy approaches in lymphomas.
    Leuk Lymphoma. 2024;65:1923-1933.
    >> Share

  92. LANIER CM, Razavian NB, Smith S, D'Agostino RB Jr, et al
    The impact of initial tumor bulk in DLBCL treated with DA-EPOCH-R vs. R-CHOP: a secondary analysis of alliance/CALGB 50303.
    Leuk Lymphoma. 2024;65:2199-2206.
    >> Share

  93. SIMONSEN MR, Haunstrup LM, Severinsen FT, Jensen RK, et al
    The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study.
    Leuk Lymphoma. 2024;65:2173-2181.
    >> Share

    November 2024
  94. DESCHENES-SIMARD X, Pennisi M, Perales MA, Shah GL, et al
    Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
    Leuk Lymphoma. 2024 Nov 20:1-6. doi: 10.1080/10428194.2024.2430703.
    >> Share

  95. MISHRA P, Bhurani D, Khan MA, Nidhi, et al
    Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy.
    Leuk Lymphoma. 2024 Nov 15:1-13. doi: 10.1080/10428194.2024.2424373.
    >> Share

  96. SORIGUE M
    Follow-up in patients with lymphoma: a call for an evidence-based approach.
    Leuk Lymphoma. 2024 Nov 15:1-4. doi: 10.1080/10428194.2024.2426053.
    >> Share

    October 2024
  97. THIEBLEMONT C, Wahlin BE, Mohseninejad L, Wang K, et al
    Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.
    Leuk Lymphoma. 2024 Oct 24:1-10. doi: 10.1080/10428194.2024.2416577.
    >> Share

  98. FASSER D, Lewis K, Leslie C, Cull G, et al
    Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era.
    Leuk Lymphoma. 2024 Oct 18:1-4. doi: 10.1080/10428194.2024.2416563.
    >> Share

  99. HAN J, McCall CM, Isom S, Smith WM, et al
    High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy.
    Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2414899.
    >> Share

  100. YANG L, Zeng LJ, Wang S, Wei LQ, et al
    Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing DeltaSUVlbm between baseline and interim (18)F-FDG PET/CT scans.
    Leuk Lymphoma. 2024 Oct 15:1-8. doi: 10.1080/10428194.2024.2416026.
    >> Share

  101. SOMASUNDARAM E, Abramson JS
    Double hit lymphoma: contemporary understanding and practices.
    Leuk Lymphoma. 2024 Oct 8:1-8. doi: 10.1080/10428194.2024.2412295.
    >> Share

  102. SHADMAN M, Salkar M, Srivastava B, Karve S, et al
    Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814.
    >> Share

    September 2024
  103. USTA S, Misura A, Rashedi I, Amitai I, et al
    Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2024 Sep 27:1-11. doi: 10.1080/10428194.2024.2403668.
    >> Share

  104. FUREDER W, Skrabs C, Tobudic S
    Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab.
    Leuk Lymphoma. 2024 Sep 23:1-3. doi: 10.1080/10428194.2024.2404246.
    >> Share

  105. GURUMURTHI A, Bantilan KS, Hamlin PA, Kumar A, et al
    A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
    Leuk Lymphoma. 2024 Sep 20:1-4. doi: 10.1080/10428194.2024.2398658.
    >> Share

  106. ROBINSON S, Wu S, Lade S, Tam CS, et al
    CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma.
    Leuk Lymphoma. 2024 Sep 18:1-4. doi: 10.1080/10428194.2024.2404954.
    >> Share

  107. ANNIBALI O, Merli M, Minoia C, Mancuso S, et al
    Vaccination strategies for patients with lymphoma treated in early lines of therapies: a real-world practice survey among Fondazione Italiana Linfomi centers.
    Leuk Lymphoma. 2024 Sep 18:1-6. doi: 10.1080/10428194.2024.2405866.
    >> Share

  108. MILSHTEYN L, Villamejor A, Merchant A, Lownik J, et al
    A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications.
    Leuk Lymphoma. 2024 Sep 18:1-7. doi: 10.1080/10428194.2024.2404253.
    >> Share

  109. MEHTAP O, Toptas T, Dal MS, Karadag FK, et al
    A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients.
    Leuk Lymphoma. 2024 Sep 13:1-9. doi: 10.1080/10428194.2024.2395458.
    >> Share

  110. DUFFLES G, Braga A, Silveira T, Novis Y, et al
    Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study.
    Leuk Lymphoma. 2024 Sep 10:1-7. doi: 10.1080/10428194.2024.2401098.
    >> Share

  111. HARROP S, Dickinson M
    Eligibility for clinical trials in diffuse large B-cell lymphoma: are we sweating the small stuff?
    Leuk Lymphoma. 2024 Sep 5:1-3. doi: 10.1080/10428194.2024.2400217.
    >> Share

  112. BRAUN APG, Herrera A
    Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse.
    Leuk Lymphoma. 2024 Sep 3:1-8. doi: 10.1080/10428194.2024.2397072.
    >> Share

  113. SHAULOV A, Gross Even-Zohar N, Aumann S, Haran A, et al
    Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature.
    Leuk Lymphoma. 2024 Sep 3:1-5. doi: 10.1080/10428194.2024.2396043.
    >> Share

  114. NARITA K, Okamoto A, Iba S, Tabata R, et al
    Analysis of the clinical features and outcomes of relapsed intravascular large B-cell lymphoma: a single center study.
    Leuk Lymphoma. 2024 Sep 3:1-4. doi: 10.1080/10428194.2024.2389213.
    >> Share

  115. BROCCOLI A, Margiotta-Casaluci G, Pagani C, Steffanoni S, et al
    Routine follow-up practices in patients with lymphoma: a nationwide survey by the Italian lymphoma foundation.
    Leuk Lymphoma. 2024 Sep 3:1-4. doi: 10.1080/10428194.2024.2396048.
    >> Share

  116. DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al
    Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660.
    >> Share

  117. KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al
    RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258.
    >> Share

    August 2024
  118. BRAND MVD, Tzankov A, Scheijde-Vermeulen M, Barbe E, et al
    The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?
    Leuk Lymphoma. 2024 Aug 29:1-4. doi: 10.1080/10428194.2024.2396542.
    >> Share

  119. FRUTOS DIAZ-ALEJO J, Morillo-Giles D, Diaz de la Pinta FJ, Manso R, et al
    New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis.
    Leuk Lymphoma. 2024 Aug 15:1-4. doi: 10.1080/10428194.2024.2390567.
    >> Share

  120. MENEZ S, Bourbon E, Gounot R, Tudesq JJ, et al
    CAR T-cells in very elderly (>/=80 years) lymphoma patients: a DESCAR-T analysis.
    Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2387731.
    >> Share

  121. ROSSETTI S, Juul SJ, van der Kaaij MAE, Fortpied C, et al
    Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials.
    Leuk Lymphoma. 2024 Aug 12:1-5. doi: 10.1080/10428194.2024.2390565.
    >> Share

  122. SOSA-ROMERO JT, Castillo-Martinez L, Gabutti-Thomas JA, Agreda-Va Squez GP, et al
    Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2024 Aug 2:1-10. doi: 10.1080/10428194.2024.2386591.
    >> Share

  123. MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al
    Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively.
    Leuk Lymphoma. 2024;65:1100-1109.
    >> Share

    July 2024
  124. LI Y, Sheng Q, Li J, Liu W, et al
    Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis.
    Leuk Lymphoma. 2024 Jul 31:1-14. doi: 10.1080/10428194.2024.2371500.
    >> Share

  125. AHN J, Ouyang Y, Velasco G, Eapen A, et al
    A case report of solitary presentations of large B-cell lymphoma of immune-privileged sites (IP-LBCL) in the testis, vitreous body, and skin.
    Leuk Lymphoma. 2024 Jul 30:1-4. doi: 10.1080/10428194.2024.2385495.
    >> Share

  126. SORELLA S, Assanto GM, D'Elia GM, Annechini G, et al
    A case of posterior reversible encephalopathy syndrome (PRES) in an elderly patient with advanced classical Hodgkin Lymphoma during frontline treatment with brentuximab vedotin plus AVD.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2383728.
    >> Share

  127. TOHO M, Yasunaga M, Masuda Y, Shimura A, et al
    Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
    Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646.
    >> Share

  128. JACOBSEN E, Plant A, Redd R, Armand P, et al
    A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma.
    Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2381651.
    >> Share

  129. SANTOS LOURO L, Dimopoulos Y, Leventaki V, Vega F, et al
    Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14.
    Leuk Lymphoma. 2024 Jul 21:1-4. doi: 10.1080/10428194.2024.2381014.
    >> Share

  130. ADEUYAN O, Ouseph MM, Bao L, Kluk MJ, et al
    A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing.
    Leuk Lymphoma. 2024 Jul 17:1-5. doi: 10.1080/10428194.2024.2374455.
    >> Share

  131. CROMBIE JL, Jun M, Wang T, Mutebi A, et al
    Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2024 Jul 16:1-11. doi: 10.1080/10428194.2024.2371472.
    >> Share

  132. VIJENTHIRA A, Li X, Crump M, Hay AE, et al
    Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.
    Leuk Lymphoma. 2024 Jul 9:1-8. doi: 10.1080/10428194.2024.2370437.
    >> Share

  133. J WU J, Wade SW, Itani T, Castaigne JG, et al
    Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
    Leuk Lymphoma. 2024 Jul 8:1-14. doi: 10.1080/10428194.2024.2369653.
    >> Share

  134. ZHANG JR, Wu SY, Jain P, Ok CY, et al
    Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center.
    Leuk Lymphoma. 2024 Jul 7:1-4. doi: 10.1080/10428194.2024.2374457.
    >> Share

  135. STEWART C, Owen C, Chua N, Peters A, et al
    Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2024 Jul 5:1-4. doi: 10.1080/10428194.2024.2373323.
    >> Share

  136. ZHANG X, Chai Y, Lib C D W, Zhao P, et al
    Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma?
    Leuk Lymphoma. 2024 Jul 5:1-6. doi: 10.1080/10428194.2024.2370433.
    >> Share

    June 2024
  137. ZAIN J, Lunning M, Rosen S
    Experience of using venetoclax in relapsed T- cell lymphoma.
    Leuk Lymphoma. 2024 Jun 17:1-2. doi: 10.1080/10428194.2024.2363418.
    >> Share

  138. HONG D, Yin M, Li J, Deng Z, et al
    Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study.
    Leuk Lymphoma. 2024 Jun 11:1-11. doi: 10.1080/10428194.2024.2364830.
    >> Share

  139. CHANG JE, Wang T, Kim K, Folstad M, et al
    Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
    >> Share

  140. ANNIBALI O, Castellino A, Cenfra N, Ciccarone M, et al
    Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care).
    Leuk Lymphoma. 2024 Jun 7:1-8. doi: 10.1080/10428194.2024.2361358.
    >> Share

  141. SHOUSE G, Chen L, Siddiqi T, Muir A, et al
    A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841.
    >> Share

  142. LEWIS KL, Cheah CY
    The value of bispecific antibodies in relapsed and refractory DLBCL.
    Leuk Lymphoma. 2024;65:720-735.
    >> Share

    May 2024
  143. HOROWITZ NA, Abed Al Wahad A, Bettman NP, Ringelstein-Harlev S, et al
    Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model.
    Leuk Lymphoma. 2024 May 23:1-4. doi: 10.1080/10428194.2024.2353879.
    >> Share

  144. LIU Y, Ma X, Wu X, Hou X, et al
    Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B, high TCL1A expression, or over- expressed MYC/BCL-2.
    Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2343779.
    >> Share

  145. DI M, Su CT, Cowan AJ, Gopal AK, et al
    Mitigating time toxicity in lymphoma and multiple myeloma.
    Leuk Lymphoma. 2024 May 15:1-12. doi: 10.1080/10428194.2024.2352086.
    >> Share

  146. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
    Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
    >> Share

  147. CHERIAN S, Modelevsky L, Reiner AS, Grommes C, et al
    Treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center.
    Leuk Lymphoma. 2024 May 14:1-4. doi: 10.1080/10428194.2024.2343778.
    >> Share

  148. XING Y, Ye K, Li C, He J, et al
    Risk factors for treatment-related bone loss and osteoporosis in patients with follicular lymphoma.
    Leuk Lymphoma. 2024 May 6:1-9. doi: 10.1080/10428194.2024.2348113.
    >> Share

  149. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
    Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
    Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
    >> Share

  150. TABARI E, Lovejoy AF, Lin H, Bolen CR, et al
    NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.
    Leuk Lymphoma. 2024;65:618-628.
    >> Share

  151. TUCCI A, Masina L, Luminari S
    Curative intent therapy for DLBCL in the elderly.
    Leuk Lymphoma. 2024;65:560-569.
    >> Share

    April 2024
  152. VON ROEMELING C, Ferreri AJM, Soussain C, Tun HW, et al
    Targets and treatments in primary CNS lymphoma.
    Leuk Lymphoma. 2024 Apr 24:1-13. doi: 10.1080/10428194.2024.2342560.
    >> Share

  153. MCNALLY GA, Aossey CM, Wiczer T, Sinnott LT, et al
    A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH +/- R: does HIV status matter?
    Leuk Lymphoma. 2024 Apr 22:1-7. doi: 10.1080/10428194.2024.2340051.
    >> Share

  154. ALZAHRANI M, Villa D
    Management of relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2024 Apr 18:1-11. doi: 10.1080/10428194.2024.2338851.
    >> Share

  155. TA A, Kaur S, Mader M, Franklin K, et al
    The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA).
    Leuk Lymphoma. 2024 Apr 15:1-10. doi: 10.1080/10428194.2024.2338856.
    >> Share

  156. SANCHO JM, Abrisqueta P, Kumar A, Cordoba R, et al
    Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL?112).
    Leuk Lymphoma. 2024 Apr 10:1-11. doi: 10.1080/10428194.2024.2331626.
    >> Share

  157. SCHAFF L, Nayak L, Grommes C
    Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Leuk Lymphoma. 2024 Apr 10:1-13. doi: 10.1080/10428194.2024.2333985.
    >> Share

  158. CUI C, Feng C, Rosenthal N, Wade SW, et al
    Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States.
    Leuk Lymphoma. 2024 Apr 3:1-10. doi: 10.1080/10428194.2024.2331084.
    >> Share

  159. ATTYGALLE AD, Chan JKC, Coupland SE, Du MQ, et al
    The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors - an overview and update.
    Leuk Lymphoma. 2024;65:413-429.
    >> Share

  160. ATALLAH-YUNES SA, Khurana A, Maurer M
    Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.
    Leuk Lymphoma. 2024;65:430-439.
    >> Share

  161. SONG Y, Li J, Zhou K, Ke X, et al
    Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2024 Apr 1:1-6. doi: 10.1080/10428194.2024.2310141.
    >> Share

    March 2024
  162. RYU TIGER YK, Jain S, Barta SK, Tolu S, et al
    Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 22:1-10. doi: 10.1080/10428194.2024.2329996.
    >> Share

  163. TZIONI MM, Clipson A, Chen Z, Cucco F, et al
    Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 22:1-5. doi: 10.1080/10428194.2024.2332508.
    >> Share

  164. GAO LR, Wang X, Wu Y, Feng XL, et al
    Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma.
    Leuk Lymphoma. 2024 Mar 20:1-12. doi: 10.1080/10428194.2024.2329328.
    >> Share

  165. ITCHAKI G, Jarhovsky O, Castillo JJ, Hassan H, et al
    Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.
    Leuk Lymphoma. 2024 Mar 19:1-7. doi: 10.1080/10428194.2024.2332499.
    >> Share

  166. LI L, Yang W, Pan Y, Ye R, et al
    Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 18:1-16. doi: 10.1080/10428194.2024.2328227.
    >> Share

  167. RAMALINGAM TR
    Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma.
    Leuk Lymphoma. 2024 Mar 14:1-2. doi: 10.1080/10428194.2024.2330707.
    >> Share

  168. GORDON MJ, Dubois S, Bryant B, Ng S, et al
    A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 9:1-4. doi: 10.1080/10428194.2024.2326847.
    >> Share

  169. HILL BT, Chen Y, Jagadeesh D, Dean R, et al
    Lenalidomide, rituximab (R(2)), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
    Leuk Lymphoma. 2024 Mar 8:1-6. doi: 10.1080/10428194.2024.2325636.
    >> Share

  170. AKINGBEMI W, Kurtz G, Yegya-Raman N, Plastaras JP, et al
    Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
    Leuk Lymphoma. 2024 Mar 7:1-4. doi: 10.1080/10428194.2024.2322033.
    >> Share

  171. LEROY M, Deramoudt L, Pinturaud M, Demaret J, et al
    A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
    Leuk Lymphoma. 2024 Mar 5:1-4. doi: 10.1080/10428194.2024.2325188.
    >> Share

  172. BRAUNSTEIN Z, Waller A, Dotson E, McLaughlin E, et al
    Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.
    Leuk Lymphoma. 2024;65:301-311.
    >> Share

    February 2024
  173. MINSON A, Dickinson M
    Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2024 Feb 29:1-2. doi: 10.1080/10428194.2024.2320833.
    >> Share

  174. WEI C, Zhai F, Jia C, Zhang W, et al
    Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma.
    Leuk Lymphoma. 2024 Feb 22:1-4. doi: 10.1080/10428194.2024.2316252.
    >> Share

  175. TASHAKORI M, Medeiros LJ
    Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms.
    Leuk Lymphoma. 2024 Feb 21:1-5. doi: 10.1080/10428194.2024.2319691.
    >> Share

  176. NEMEC R, Scherrer-Crosbie M, Abramson JS, Redd R, et al
    Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
    Leuk Lymphoma. 2024 Feb 21:1-6. doi: 10.1080/10428194.2024.2317343.
    >> Share

  177. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    >> Share

  178. OSTERGAARD S, Schejbel L, Breinholt MF, Pedersen MO, et al
    Mutational landscape in Waldenstrom macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
    Leuk Lymphoma. 2024 Feb 10:1-10. doi: 10.1080/10428194.2024.2313623.
    >> Share

  179. MAGRO CM, Kalomeris T, Shreve CR, Geyer JT, et al
    Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration.
    Leuk Lymphoma. 2024 Feb 5:1-9. doi: 10.1080/10428194.2024.2310139.
    >> Share

  180. GRIEVE C, Joseph A, Drullinsky P, Zelenetz AD, et al
    Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
    Leuk Lymphoma. 2024;65:235-241.
    >> Share

    January 2024
  181. LEI MM, Sorial MN, Lou U, Yu M, et al
    Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
    >> Share

  182. ARYA S, Mozessohn L, Gong I, Faught N, et al
    The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study.
    Leuk Lymphoma. 2024 Jan 24:1-9. doi: 10.1080/10428194.2024.2306463.
    >> Share

  183. LIONEL AC, Gurumurthi A, Fetooh A, Eldaya R, et al
    Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2024 Jan 22:1-5. doi: 10.1080/10428194.2024.2304622.
    >> Share

  184. GRAVENMIER C, Shah B, Hussaini M, Zhang L, et al
    Chimeric antigen receptor T-cells might unmask transdifferentiated histiocytic sarcoma during diffuse large B-cell lymphoma treatment.
    Leuk Lymphoma. 2024 Jan 19:1-5. doi: 10.1080/10428194.2023.2301038.
    >> Share

  185. JIN Q, Jiang H, Yue N, Zhang L, et al
    The prognostic value of CD8(+) CTLs, CD163(+) TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma.
    Leuk Lymphoma. 2024 Jan 10:1-9. doi: 10.1080/10428194.2023.2296364.
    >> Share

  186. LAORUANGROJ C, Atherton PJ, Wiseman GA, Ansell S, et al
    The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
    Leuk Lymphoma. 2024 Jan 8:1-6. doi: 10.1080/10428194.2023.2295792.
    >> Share

  187. DICKINSON M, Martinez-Lopez J, Jousseaume E, Yang H, et al
    Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
    Leuk Lymphoma. 2024 Jan 5:1-10. doi: 10.1080/10428194.2023.2289854.
    >> Share

  188. VIVIANI S, Vanazzi A, Frassoni S, Rusconi C, et al
    High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
    Leuk Lymphoma. 2024 Jan 2:1-12. doi: 10.1080/10428194.2023.2298273.
    >> Share

  189. GORDON ER, Kwinta BD, Schreidah CM, Fahmy LM, et al
    Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes.
    Leuk Lymphoma. 2024;65:48-54.
    >> Share

  190. RIVERA-FRANCIA VM, Failoc-Rojas VE, Villacorta-Carranza R, Leon Garrido-Lecca A, et al
    Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.
    Leuk Lymphoma. 2024;65:37-47.
    >> Share

    December 2023
  191. HARRYSSON S, Eloranta S, Ekberg S, Enblad G, et al
    Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy.
    Leuk Lymphoma. 2023 Dec 22:1-4. doi: 10.1080/10428194.2023.2296361.
    >> Share

  192. KANEDA Y, Kanemura N, Nakamura N, Ikoma Y, et al
    The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2023 Dec 20:1-7. doi: 10.1080/10428194.2023.2295787.
    >> Share

  193. KUIPERS MT, Spanjaart AM, Bonifazi F, diBlasi R, et al
    Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.
    Leuk Lymphoma. 2023 Dec 9:1-4. doi: 10.1080/10428194.2023.2288804.
    >> Share

  194. KAWASAKI N, Tomita M, Yamashita-Kashima Y, Yoshimura Y, et al
    Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
    Leuk Lymphoma. 2023;64:1938-1948.
    >> Share

  195. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
    Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
    Leuk Lymphoma. 2023;64:2333-2337.
    >> Share

  196. REYNOLDS G, Anderson MA, Thursky K, Teh BW, et al
    Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis.
    Leuk Lymphoma. 2023;64:2057-2070.
    >> Share

  197. PENA J, Cull D, Strowd LC, Vaidya R, et al
    Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoides.
    Leuk Lymphoma. 2023;64:2202-2207.
    >> Share

    November 2023
  198. CHOHAN KL, Bansal R, Hathcock MA, Paludo J, et al
    Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
    Leuk Lymphoma. 2023 Nov 30:1-5. doi: 10.1080/10428194.2023.2285236.
    >> Share

  199. ZHONG Q, Liu Y, Wu Y, Liu X, et al
    Impact of age on long-term relative survival benefit of radiotherapy for early-stage grade I-II follicular lymphoma from the SEER database (2000-2015).
    Leuk Lymphoma. 2023 Nov 21:1-11. doi: 10.1080/10428194.2023.2283296.
    >> Share

  200. FOUILLET L, Daguenet E, Tavernier E, Ghesquieres H, et al
    Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.
    Leuk Lymphoma. 2023 Nov 15:1-5. doi: 10.1080/10428194.2023.2281270.
    >> Share

  201. PACHECO JM, Forchhammer S, Otto F, Fend F, et al
    Primary cutaneous anaplastic large cell lymphoma with DUSP22-rearrangement presenting as a mimicker of mycosis fungoides: a case report and review of the literature.
    Leuk Lymphoma. 2023 Nov 7:1-5. doi: 10.1080/10428194.2023.2276678.
    >> Share

  202. NEWSAM AD, Coughlin CA, Trabolsi A, Schatz JH, et al
    Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma.
    Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2258244.
    >> Share

  203. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
    Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
    Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
    >> Share

  204. DUAN Y, Gao H, Zhou C, Jin L, et al
    Primary central nervous system lymphoma in children - a rare but serious disease with good prognosis from a single center in China.
    Leuk Lymphoma. 2023 Nov 2:1-6. doi: 10.1080/10428194.2023.2263120.
    >> Share

    October 2023
  205. VILLENEUVE PJ, Harris SA
    Re: exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Oct 30:1-3. doi: 10.1080/10428194.2023.2275529.
    >> Share

  206. KUMAR AJ, Pearson LK, Wong JB, Friedberg JW, et al
    Understanding treatment decisions for Hodgkin lymphoma: a qualitative study.
    Leuk Lymphoma. 2023 Oct 28:1-9. doi: 10.1080/10428194.2023.2256913.
    >> Share

  207. WOOTEN SV, Amini B, Roth M, Leung CH, et al
    Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report.
    Leuk Lymphoma. 2023 Oct 25:1-7. doi: 10.1080/10428194.2023.2273747.
    >> Share

  208. ASMUSSEN A, Quintanilla-Martinez L, Larsen M, Fagerberg C, et al
    Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case.
    Leuk Lymphoma. 2023 Oct 23:1-5. doi: 10.1080/10428194.2023.2264425.
    >> Share

  209. HESS G, Dreyling M, Oberic L, Gine E, et al
    Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2023 Oct 16:1-12. doi: 10.1080/10428194.2023.2268228.
    >> Share

  210. MCGOUGH SF, Shamas N, Wang J, Jaber M, et al
    Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
    Leuk Lymphoma. 2023 Oct 15:1-10. doi: 10.1080/10428194.2023.2262066.
    >> Share

  211. GRIBBIN C, Chen J, Martin P, Ruan J, et al
    Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
    Leuk Lymphoma. 2023 Oct 6:1-13. doi: 10.1080/10428194.2023.2264430.
    >> Share

  212. STUVER R, Vardhana SA, Bedmutha A, Chan KK, et al
    Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab.
    Leuk Lymphoma. 2023 Oct 5:1-3. doi: 10.1080/10428194.2023.2262641.
    >> Share

  213. IKEDA D, Oura M, Uehara A, Tabata R, et al
    Efficacy of darinaparsin for EBV-associated B-cell lymphoma in a heavily treated elderly patient with angioimmunoblastic T-cell lymphoma: a case report.
    Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2265001.
    >> Share

  214. ZAK T, Santana-Santos L, Gao J, Behdad A, et al
    Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma.
    Leuk Lymphoma. 2023 Oct 5:1-11. doi: 10.1080/10428194.2023.2264429.
    >> Share

    September 2023
  215. IP A, Petrillo A, Della Pia A, Lee GG, et al
    Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2023 Sep 23:1-11. doi: 10.1080/10428194.2023.2259528.
    >> Share

  216. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
    Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
    >> Share

  217. ABDULRAHMAN N, Leo R, Boumenar HA, Ahmad F, et al
    Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
    Leuk Lymphoma. 2023 Sep 14:1-13. doi: 10.1080/10428194.2023.2256909.
    >> Share

  218. FRERET ME, Tringale KR, Boe L, Imber BS, et al
    Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.
    Leuk Lymphoma. 2023 Sep 14:1-7. doi: 10.1080/10428194.2023.2255706.
    >> Share

  219. GORDON MJ, Duan Z, Zhao H, Nastoupil L, et al
    Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
    Leuk Lymphoma. 2023 Sep 14:1-11. doi: 10.1080/10428194.2023.2256908.
    >> Share

  220. DAHI PB, Kenny S, Flynn J, Devlin SM, et al
    Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
    Leuk Lymphoma. 2023 Sep 10:1-7. doi: 10.1080/10428194.2023.2256912.
    >> Share

  221. LEICH E, Brodtkorb M, Schmidt T, Altenbuchinger M, et al
    Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.
    Leuk Lymphoma. 2023 Sep 8:1-11. doi: 10.1080/10428194.2023.2240462.
    >> Share

  222. GOENKA L, Kumar SM, Essakky S, Rajasulochana SR, et al
    Cost-effectiveness of response-adapted therapy (RAT) for advanced Hodgkin's Lymphoma compared with conventional treatment in India: a Markov-model based analysis.
    Leuk Lymphoma. 2023 Sep 5:1-7. doi: 10.1080/10428194.2023.2249154.
    >> Share

    August 2023
  223. BECERRIL-RICO J, Delgado-Montes YA, Ortiz-Sanchez E
    Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Leuk Lymphoma. 2023 Aug 7:1-10. doi: 10.1080/10428194.2023.2243357.
    >> Share

    March 2023
  224. BAGGIO D, Wellard C, Chung E, Talaulikar D, et al
    Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
    Leuk Lymphoma. 2023;64:621-627.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016